MX2015013378A - Uso de sedoheptulosa para la prevencion y tratamiento de inflamacion. - Google Patents
Uso de sedoheptulosa para la prevencion y tratamiento de inflamacion.Info
- Publication number
- MX2015013378A MX2015013378A MX2015013378A MX2015013378A MX2015013378A MX 2015013378 A MX2015013378 A MX 2015013378A MX 2015013378 A MX2015013378 A MX 2015013378A MX 2015013378 A MX2015013378 A MX 2015013378A MX 2015013378 A MX2015013378 A MX 2015013378A
- Authority
- MX
- Mexico
- Prior art keywords
- sedoheptulose
- inflammation
- prevention
- treatment
- invention describes
- Prior art date
Links
- HAIWUXASLYEWLM-UHFFFAOYSA-N D-manno-Heptulose Natural products OCC1OC(O)(CO)C(O)C(O)C1O HAIWUXASLYEWLM-UHFFFAOYSA-N 0.000 title abstract 2
- 206010061218 Inflammation Diseases 0.000 title abstract 2
- HSNZZMHEPUFJNZ-UHFFFAOYSA-N L-galacto-2-Heptulose Natural products OCC(O)C(O)C(O)C(O)C(=O)CO HSNZZMHEPUFJNZ-UHFFFAOYSA-N 0.000 title abstract 2
- HAIWUXASLYEWLM-AZEWMMITSA-N Sedoheptulose Natural products OC[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@](O)(CO)O1 HAIWUXASLYEWLM-AZEWMMITSA-N 0.000 title abstract 2
- 230000004054 inflammatory process Effects 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- HSNZZMHEPUFJNZ-SHUUEZRQSA-N sedoheptulose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO HSNZZMHEPUFJNZ-SHUUEZRQSA-N 0.000 title abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
Abstract
La invención describe sedoheptulosa para usarse en la prevención o tratamiento de inflamación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13160443.1A EP2781219A1 (en) | 2013-03-21 | 2013-03-21 | Use of sedoheptulose for prevention or treatment of inflammation |
| PCT/EP2014/055679 WO2014147214A1 (en) | 2013-03-21 | 2014-03-21 | Use of sedoheptulose for prevention or treatment of inflammation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015013378A true MX2015013378A (es) | 2016-01-08 |
| MX385322B MX385322B (es) | 2025-03-18 |
Family
ID=47901873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015013378A MX385322B (es) | 2013-03-21 | 2014-03-21 | Uso de sedoheptulosa para la prevención y tratamiento de inflamación. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9694026B2 (es) |
| EP (2) | EP2781219A1 (es) |
| JP (1) | JP6388635B2 (es) |
| CN (2) | CN115364112A (es) |
| AU (1) | AU2014234230B2 (es) |
| BR (1) | BR112015023463A2 (es) |
| CA (1) | CA2903151C (es) |
| DK (1) | DK2976089T3 (es) |
| ES (1) | ES2930249T3 (es) |
| HU (1) | HUE060237T2 (es) |
| MX (1) | MX385322B (es) |
| NZ (1) | NZ711523A (es) |
| PL (1) | PL2976089T3 (es) |
| PT (1) | PT2976089T (es) |
| WO (1) | WO2014147214A1 (es) |
| ZA (1) | ZA201506396B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2781218A1 (en) | 2013-03-21 | 2014-09-24 | Medizinische Universität Wien | Use of sedoheptulose as a nutritional supplement |
| CN106309458A (zh) * | 2016-07-28 | 2017-01-11 | 中南大学湘雅医院 | 2‑脱氧‑d‑葡萄糖及其在药学上可接受的盐在制备治疗银屑病药物方面的应用 |
| CN116602363B (zh) * | 2023-06-17 | 2025-01-24 | 广东驱动力生物科技集团股份有限公司 | 一种治疗或预防肉食性鱼脂肪肝的助剂及其制备方法 |
| CN119405681B (zh) * | 2024-11-04 | 2025-09-23 | 新乡医学院 | 核糖-5磷酸在制备治疗炎症性疾病药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0221728B1 (en) * | 1985-10-22 | 1992-07-15 | Anthony N. Silvetti, Sr. | Monosaccharide containing wound healing preparation |
| JPH04335877A (ja) | 1991-05-13 | 1992-11-24 | Eimu:Kk | 十薬食品・飲料並びに製造法 |
| US9492582B2 (en) * | 2000-11-08 | 2016-11-15 | Fxs Ventures, Llc | Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers |
| US20090252834A1 (en) | 2004-05-10 | 2009-10-08 | Michael Griffin Hayek | Compositions comprising glucose anti-metabolites |
| WO2006027796A2 (en) | 2004-07-30 | 2006-03-16 | Pharmed Medicare Pty. Ltd. | Reduced calorie sweetener composition |
| AU2006218840A1 (en) | 2005-02-28 | 2006-09-08 | Mcneil Nutritionals, Llc | Brown sugar substitute |
| JP5048238B2 (ja) * | 2005-11-16 | 2012-10-17 | エスエス製薬株式会社 | ウワウルシ乾燥エキス含有経口製剤 |
| GB0720516D0 (en) | 2007-10-18 | 2007-11-28 | Cadbury Schweppes Plc | Comestible products |
| KR100912277B1 (ko) * | 2007-11-21 | 2009-08-17 | 한국생명공학연구원 | 내열성 효소를 이용하여 세도헵툴로스를 제조하는 방법 |
| CN101919872B (zh) * | 2010-07-21 | 2011-12-07 | 广东粤龙药业有限公司 | 景酮糖酐在制备抗乙肝药物中的应用 |
| GB201303698D0 (en) | 2012-10-26 | 2013-04-17 | Tate & Lyle Ingredients | Sweetener syrups |
| CN103059071B (zh) * | 2013-01-08 | 2016-03-16 | 华东理工大学 | 一种单糖的纳滤分离方法 |
| EP2781218A1 (en) | 2013-03-21 | 2014-09-24 | Medizinische Universität Wien | Use of sedoheptulose as a nutritional supplement |
-
2013
- 2013-03-21 EP EP13160443.1A patent/EP2781219A1/en not_active Withdrawn
-
2014
- 2014-03-21 CN CN202211174309.3A patent/CN115364112A/zh active Pending
- 2014-03-21 NZ NZ711523A patent/NZ711523A/en not_active IP Right Cessation
- 2014-03-21 DK DK14711754.3T patent/DK2976089T3/da active
- 2014-03-21 AU AU2014234230A patent/AU2014234230B2/en not_active Ceased
- 2014-03-21 CA CA2903151A patent/CA2903151C/en active Active
- 2014-03-21 MX MX2015013378A patent/MX385322B/es unknown
- 2014-03-21 CN CN201480028530.5A patent/CN105283188A/zh active Pending
- 2014-03-21 US US14/778,850 patent/US9694026B2/en active Active
- 2014-03-21 ES ES14711754T patent/ES2930249T3/es active Active
- 2014-03-21 EP EP14711754.3A patent/EP2976089B1/en active Active
- 2014-03-21 HU HUE14711754A patent/HUE060237T2/hu unknown
- 2014-03-21 WO PCT/EP2014/055679 patent/WO2014147214A1/en not_active Ceased
- 2014-03-21 PL PL14711754.3T patent/PL2976089T3/pl unknown
- 2014-03-21 JP JP2016503672A patent/JP6388635B2/ja not_active Expired - Fee Related
- 2014-03-21 PT PT147117543T patent/PT2976089T/pt unknown
- 2014-03-21 BR BR112015023463A patent/BR112015023463A2/pt not_active IP Right Cessation
-
2015
- 2015-09-01 ZA ZA2015/06396A patent/ZA201506396B/en unknown
-
2017
- 2017-06-14 US US15/622,235 patent/US10660910B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2976089A1 (en) | 2016-01-27 |
| ES2930249T3 (es) | 2022-12-09 |
| US20170281661A1 (en) | 2017-10-05 |
| CN105283188A (zh) | 2016-01-27 |
| PL2976089T3 (pl) | 2023-01-30 |
| JP2016516077A (ja) | 2016-06-02 |
| DK2976089T3 (da) | 2022-11-07 |
| US9694026B2 (en) | 2017-07-04 |
| US20160045525A1 (en) | 2016-02-18 |
| WO2014147214A1 (en) | 2014-09-25 |
| MX385322B (es) | 2025-03-18 |
| NZ711523A (en) | 2020-09-25 |
| HUE060237T2 (hu) | 2023-02-28 |
| CA2903151A1 (en) | 2014-09-25 |
| EP2976089B1 (en) | 2022-08-17 |
| PT2976089T (pt) | 2022-11-22 |
| EP2781219A1 (en) | 2014-09-24 |
| AU2014234230B2 (en) | 2018-08-09 |
| JP6388635B2 (ja) | 2018-09-12 |
| CA2903151C (en) | 2021-11-30 |
| ZA201506396B (en) | 2018-05-30 |
| US10660910B2 (en) | 2020-05-26 |
| AU2014234230A1 (en) | 2015-09-17 |
| CN115364112A (zh) | 2022-11-22 |
| BR112015023463A2 (pt) | 2017-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283086A (en) | Use of cannabidiol in the treatment of tuberous sclerosis complex | |
| CL2015002562A1 (es) | Anticuerpos e inmunoconjugados anti-b7-h4 | |
| GB2548873B (en) | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome | |
| GB201703115D0 (en) | Use of cannabinoids in the treatment of leukaemia | |
| MX2015012326A (es) | Anticuerpos anti-crth2 y su uso. | |
| ECSP17018120A (es) | Triazolopirazinonas como inhibidores de pde1 | |
| PL3157511T3 (pl) | Zastosowanie kannabinoidów w leczeniu padaczki | |
| PL3503890T3 (pl) | Stosowanie pridopidyny w leczeniu dystonii | |
| CL2015003704A1 (es) | Péptidos y peptidomiméticos en usos de combinación y tratamientos para la subpoblacion de pacientes con cáncer | |
| DOP2017000254A (es) | Imidazopirazinonas como inhibidores de pde1 | |
| PL3464368T3 (pl) | Zastosowanie przeciwciała anty-pd-1 w skojarzeniu z przeciwciałem anty-cd30 w leczeniu chłoniaka | |
| MX2015014713A (es) | Uso de una composicion que comprende aceite de pescado y jugo para el tratamiento y/o postratamiento de cancer. | |
| MX374385B (es) | Apilimod para uso en el tratamiento de melanoma. | |
| PL3236960T3 (pl) | Fluralaner do zastosowania w leczeniu demodekozy | |
| IL247435A0 (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
| ECSP16061208A (es) | Quinazolin-thf-aminas como inhibidores de pde1 | |
| DOP2016000263A (es) | Quinazolin-thf-aminas halogenadas como inhibidores de pde1 | |
| ECSP16071574A (es) | Hexahidrofuropirroles como inhibidores de pde1 | |
| PH12016501838A1 (en) | Compounds and their methods of use | |
| MX2015013378A (es) | Uso de sedoheptulosa para la prevencion y tratamiento de inflamacion. | |
| PL3405197T3 (pl) | Zastosowanie delgocytynibu w leczeniu przewlekłego wyprysku dłoni | |
| IL311363A (en) | Compositions for use in treating cognitive impairment | |
| PT3383381T (pt) | Composto para uso na prevenção e tratamento de doenças neurodegenerativas | |
| AU355724S (en) | Tensioner bracket | |
| TH1801002163A (th) | เพปไทด์เพื่อใช้ในการรักษาป้องกันและเยียวยาภาวะศีรษะล้าน |